Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Zogenix Sees Its Pipeline Drugs Continue to Be Developed in Japan after UCB Deal
March 2, 2022
- Drugs Might Get Hit by SWIFT Ban on Russia Even If Exempted from Trade Sanctions
March 1, 2022
- Ozempic Shipment Suspension Expected from March: Novo
March 1, 2022
- Ono Sues AstraZeneca over PD-L1 Patent, Seeks 32 Billion Yen in Damage
March 1, 2022
- Shionogi, Ube Tie Up on Anti-RSV Drug, Eye Clinical Trial Launch in FY2023
March 1, 2022
- Mitsubishi Tanabe Snaps Up Seed Compounds through Research Collaboration with Chinese Biotech
February 28, 2022
- Number of Flu Patients Plunges to 1/1,200th of Pre-COVID Levels: Survey
February 28, 2022
- Horizon Launches Japan PIII for Thyroid Eye Disease Drug
February 25, 2022
- Fuji Pharma In-Licenses Sixth Biosimilar from Alvotech
February 25, 2022
- Shionogi Files COVID-19 Pill in Japan, Seeks Conditional Approval
February 25, 2022
- Tokyo Court Rejects Chugai’s Claim over Edirol Substance Patent
February 25, 2022
- Medicago’s COVID-19 Vaccine Approved in Canada
February 25, 2022
- Enhertu Hits PFS, OS Goals in HER2 Low Breast Cancer
February 22, 2022
- BTK Inhibitor Velexbru Approved in Taiwan: Ono
February 22, 2022
- Novo Prepping for Listing of Ozempic 2 mg Version amid Supply Curbs
February 22, 2022
- Bayer Gets Eylea Biosame Approval in Japan as It Braces for Biosimilar Debuts
February 22, 2022
- UCB Japan Recalls Antiepileptic Med E Keppra IV
February 22, 2022
- Sleep Inducer Recalls by Fuji Yakuhin, Tatsumi Kagaku Tied to Tokyo Wholesaler’s Fake API Case
February 21, 2022
- BMS Japan to Kick Off Workplace Booster Program in March
February 18, 2022
- Parmodia-Deberza Combo Improves NASH in Mice: Kowa/Univ. of Tokyo
February 18, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…